{"id":"W4381715763","doi":"10.1001/jamanetworkopen.2023.19607","title":"Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Pembrolizumab; Internal medicine; Oncology; Melanoma; Clinical endpoint; Clinical trial; Censoring (clinical trials); Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353888,0.0003750573,0.0008269835,0.0003384286,0.0003690158,0.0006978811,0.0005757347,0.0005037073,0.001812087],"category_scores_gemma":[0.001773051,0.0001484095,0.00115415,0.000335237,0.0002673757,0.0004581954,0.0003429861,0.001008758,0.0001741196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003355722,"about_ca_system_score_gemma":0.003135867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03069779,"about_ca_topic_score_gemma":0.07620942,"domain_scores_codex":[0.9995346,0.00009022095,0.00002101776,0.00009576341,0.00008560199,0.0001729209],"domain_scores_gemma":[0.9989266,0.0001681018,0.0002356219,0.00006695815,0.00008241194,0.0005203178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5226603,0.004918016,0.369935,0.0004021032,0.002521668,0.0003719467,0.0003532781,0.005218153,0.005750576,0.0002515698,0.004085213,0.08353217],"study_design_scores_gemma":[0.01962101,0.06548549,0.9006621,0.0001354849,0.001857171,0.0003434448,0.0002536837,0.006856764,0.001762911,0.0003078101,0.00265866,0.00005552798],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979814,0.0007218281,0.00005725237,0.0001094132,0.00003553389,0.00005640132,0.0005506663,0.000008402077,0.0004790654],"genre_scores_gemma":[0.9979808,0.0002146401,0.00006080795,0.00008921746,0.00004103531,0.00004056219,0.0009170601,0.000002530798,0.0006533208],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03069779,"threshold_uncertainty_score":0.0610382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02428160445229956,"score_gpt":0.3016705749623989,"score_spread":0.2773889705100994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}